Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life: A retrospective cohort Clinical Practice Research Datalink study
Primary Care Diabetes · 2025
DOI: 10.1016/j.pcd.2025.03.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Primary Care Diabetes, 2025. Verfasst von Elizabeth Hickman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK. Elec…. Hauptthemen laut MEDLINE: Deprescriptions, Palliative Care, Practice Patterns, Physicians', Terminal Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Office for National Statistics, University of Leicester, National Institute for Health and Care Research.
Themen: Palliativpflege
Abstract (Originalsprache)
OBJECTIVES: To investigate the patterns and trends associated with deprescribing of preventive medications in the final 12 months of life in palliative patients living with multiple long-term conditions using the Clinical Practice Research Datalink. PARTICIPANTS: All patients with a medcode/readcode for palliative care assigned to their profile with a medcode/readcode for a cardiometabolic condition. All patients were on therapeutic interventions for their condition/s. PRIMARY AND SECONDARY OUTCOME MEASURES: the trends of medication deprescribing of preventive medications in the final twelve months of life in those known to be end-of-life. RESULTS: Preventive medication deprescribing was only observed in a very small cohort of patients. The findings were consistent across all six medication groups tested. Deprescribing was observed in a range of 2-60 patients with the most deprescribing efforts being associated with antihypertensive medications (n = 177), and antiplatelet medications (n = 70), and antihyperglycaemic medications (n = 10). CONCLUSIONS: Deprescribing practices are not commonplace in patients with a known end-of-life designation with low patient numbers (range 2-60) undergoing the intervention, thus potentially reducing the quality of life in these patients final twelve months of life. CPRD ID: #22_002253, linkage request 2914.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Research Centre, Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK. Electronic address: emh35@leicester.ac.uk.
- Diabetes Research Centre, Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK.
Förderung
- Office for National Statistics
- University of Leicester
- National Institute for Health and Care Research
- National Institute for Social Care and Health Research
- NIHR Leicester Biomedical Research Centre
Zitieren
APA
Hickman, E., Gillies, C., Khunti, K., & Seidu, S. (2025). Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life: A retrospective cohort Clinical Practice Research Datalink study. Primary Care Diabetes. https://doi.org/10.1016/j.pcd.2025.03.005
Vancouver
Hickman E, Gillies C, Khunti K, Seidu S. Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life: A retrospective cohort Clinical Practice Research Datalink study. Primary Care Diabetes. 2025. doi:10.1016/j.pcd.2025.03.005
BibTeX
@article{Hickman2025,
author = {Hickman, Elizabeth and Gillies, Clare and Khunti, Kamlesh and Seidu, Samuel},
title = {Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life: A retrospective cohort Clinical Practice Research Datalink study},
journal = {Primary Care Diabetes},
year = {2025},
doi = {10.1016/j.pcd.2025.03.005}
}
EUVIMED